Comment on Dawed et al. Genome-Wide Meta-Analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682

Ke Wang¹, Mai Shi¹, Aimin Yang¹, Brian Tomlinson^{1

2}, Juliana C N Chan^{1

3

4}, Elaine Chow^{1

4

5}

Affiliations

¹ Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
² Faculty of Medicine, Macau University of Science and Technology, Macau, China.
³ Hong Kong Institute of Diabetes and Obesity, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
⁴ Li Ka Shing Institute of Health Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
⁵ Phase 1 Clinical Trial Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.

Comment

Ke Wang et al. Diabetes Care. 2022.

. 2022 Apr 1;45(4):e80-e81.

doi: 10.2337/dc21-2428.

Ke Wang¹, Mai Shi¹, Aimin Yang¹, Brian Tomlinson^{1

2}, Juliana C N Chan^{1

3

4}, Elaine Chow^{1

4

5}

¹ Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
² Faculty of Medicine, Macau University of Science and Technology, Macau, China.
³ Hong Kong Institute of Diabetes and Obesity, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
⁴ Li Ka Shing Institute of Health Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
⁵ Phase 1 Clinical Trial Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.

No abstract available

Comment in

Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682.
Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang YC, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, 't Hart LM, Giacomini KM, Pearson ER; for MetGen Plus, for the DIRECT Consortium. Dawed AY, et al. Diabetes Care. 2022 Apr 1;45(4):e82-e83. doi: 10.2337/dci21-0066. Diabetes Care. 2022. PMID: 35349657 Free PMC article. No abstract available.

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas.
Dawed AY, Yee SW, Zhou K, van Leeuwen N, Zhang Y, Siddiqui MK, Etheridge A, Innocenti F, Xu F, Li JH, Beulens JW, van der Heijden AA, Slieker RC, Chang YC, Mercader JM, Kaur V, Witte JS, Lee MTM, Kamatani Y, Momozawa Y, Kubo M, Palmer CNA, Florez JC, Hedderson MM, 't Hart LM, Giacomini KM, Pearson ER; for MetGen Plus, for the DIRECT Consortium; MetGen Plus investigators:. Dawed AY, et al. Diabetes Care. 2021 Dec;44(12):2673-2682. doi: 10.2337/dc21-1152. Epub 2021 Oct 4. Diabetes Care. 2021. PMID: 34607834 Free PMC article.

1. Dawed AY, Yee SW, Zhou K, et al. .; DIRECT Consortium; MetGen Plus . Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas. Diabetes Care 2021;44:2673–2682 - PMC - PubMed
1. Link E, Parish S, Armitage J, et al. .; SEARCH Collaborative Group . SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 2008;359:789–799 - PubMed
1. Ramsey LB, Johnson SG, Caudle KE, et al. . The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423–428 - PMC - PubMed
1. Wang K, Yang A, Shi M, et al. . CYP2C19 loss-of-function polymorphisms are associated with reduced risk of sulfonylurea treatment failure in chinese patients with type 2 diabetes. Clin Pharmacol Ther 2022;111:461–469 - PMC - PubMed